We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

94 hedge funds and large institutions have $86.5M invested in Arbutus Biopharma in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

18% more funds holding

Funds holding: 80 → 94 (+14)

9% more capital invested

Capital invested by funds: $79.4M → $86.5M (+$7.03M)

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

0.96% more ownership

Funds ownership: 26.25% → 27.21% (+0.96%)

46% less call options, than puts

Call options by funds: $1.89M | Put options by funds: $3.5M

Holders
94
Holders Change
+14
Holders Change %
+17.5%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
23
Reduced
22
Closed
8
Calls
$1.89M
Puts
$3.5M
Net Calls
-$1.62M
Net Calls Change
+$586K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4M
2
Two Sigma Investments
Two Sigma Investments
New York
+$2.97M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.6M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.31M
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.19M

Top Sellers

Rank Fund Capital Flow
1
TI
Think Investments
California
-$7.1M
2
Ameriprise
Ameriprise
Minnesota
-$1.85M
3
Morgan Stanley
Morgan Stanley
New York
-$1.13M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$1.02M
5
Group One Trading
Group One Trading
Illinois
-$788K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
76
Penserra Capital Management
California
$6K -$39 -10 -0.5%
SFS
77
Sowell Financial Services
Arkansas
$4K +$2.12K +550 +59%
GWM
78
Geneos Wealth Management
Colorado
$3K – – –
JWA
79
JFS Wealth Advisors
Pennsylvania
$3K – – –
Federated Hermes
80
Federated Hermes
Pennsylvania
$3K +$3.84K +996 New
FDCDDQ
81
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.66K – – –
Royal Bank of Canada
82
Royal Bank of Canada
Ontario, Canada
$2K -$57.1K -14,798 -96%
HIA
83
Harbor Investment Advisory
Maryland
$2K – – –
PA
84
Parallel Advisors
California
$2K – – –
RG
85
Retirement Group
California
$2K – – –
AF
86
Advisornet Financial
Minnesota
$1K – – –
Daiwa Securities Group
87
Daiwa Securities Group
Japan
$1K – – –
NFG
88
Next Financial Group
Texas
$1K – – –
TF
89
TimeScale Financial
Massachusetts
$1K – – –
HI
90
Harbour Investments
Wisconsin
$1K +$772 +200 New
Fidelity Investments
91
Fidelity Investments
Massachusetts
$1K +$1.16K +300 New
TI
92
Think Investments
California
– -$7.1M -2,000,000 Closed
Simplex Trading
93
Simplex Trading
Illinois
– -$391K -101,280 -86%
6CM
94
683 Capital Management
New York
– -$355K -99,925 Closed
PCM
95
Prelude Capital Management
New York
– -$160K -45,100 Closed
MFS
96
Mirabella Financial Services
United Kingdom
– -$143K -40,280 Closed
AGM
97
Alpine Global Management
New York
– -$127K -35,825 Closed
MA
98
MYDA Advisors
New York
– -$107K -30,000 Closed
HF
99
HRT Financial
New York
– -$99K -28,054 Closed
LFG
100
Larson Financial Group
Missouri
– -$3K -901 Closed
1 2 3
4

ABUS Hedge Fund Activity: Q1 2021 in Review

94 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2021, worth a combined $86.5M — up 8.9% from $79.4M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ABUS positions and 8 closed out — a net gain of 16 holders — while 23 added to existing stakes and 22 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4M. The largest seller was Think Investments, exiting entirely with an estimated $7.1M sold.

  • 94 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2021, up from 80 in Q4 2020.
  • Funds reported $86.5M of Arbutus Biopharma stock for Q1 2021, up 8.9% quarter-over-quarter.
  • 24 funds opened new Arbutus Biopharma positions in Q1 2021 and 8 closed out, a net change of +16 holders.
  • The largest Arbutus Biopharma buyer in Q1 2021 was Point72 Asset Management, an estimated $4M added.
  • The largest Arbutus Biopharma seller in Q1 2021 was Think Investments, an estimated $7.1M sold.

Based on aggregated 13F filings for Q1 2021.